• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: AIZU OLYMPUS CO., LTD. EVIS EXERA II DUODENOVIDEOSCOPE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

AIZU OLYMPUS CO., LTD. EVIS EXERA II DUODENOVIDEOSCOPE Back to Search Results
Model Number TJF-Q180V
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Abdominal Pain (1685); Pancreatitis (4481)
Event Date 04/04/2022
Event Type  Injury  
Event Description
Olympus reviewed the following literature titled, "a prospective study of fully covered self-expandable metal stents for refractory benign pancreatic duct strictures." background: fully covered self-expanding metal stents (fcsemss) are a relatively novel option for treating painful main pancreatic duct refractory strictures in patients with chronic pancreatitis.Herein, we aimed to assess the efficacy, feasibility, and safety of fcsemss in this patient group.Methods: this prospective single-center study included patients who underwent endoscopic retrograde pancreatography with fcsems placement.The primary endpoints were the technical and clinical success rates.A reduction in visual analog scale pain score of >50% compared with that before stent placement was defined as clinical success.Secondary endpoints were resolution of pancreatic strictures on fluoroscopy during endoscopic retrograde pancreatography and the development of stent-related adverse events.Results: thirty-six patients were included in the analysis.The technical success rate was 100% (n=36) and the clinical success rate was 86.1% (n=31).There was a significant increase in stricture diameter from 1.7 mm to 3.5 mm (p<0.001) after stent removal.The mean visual analog scale pain score showed statistically significant improvement.At 19 months of follow-up, 55.6% of the patients were asymptomatic.Stent migration (16.7%), intolerable abdominal pain (8.3%), development of de novo strictures (8.3%), and mild pancreatitis (2.8%) were the most common adverse events.Conclusions: fcsems placement showed good technical and clinical success rates for achieving pain relief in patients with refractory main pancreatic duct strictures.Type of adverse events/number of patients: mild abdominal pain - 8 patients, intolerable abdominal pain - 3 patients, pancreatitis (mild) - 1 patient.This literature article requires 2 reports.The related patient identifiers are as follows: (b)(6) (fg-v435p).(b)(6) (tjf-q180v).This medwatch report is for patient identifier (b)(6).There is no report of any olympus device malfunction in any procedure described in this study.
 
Manufacturer Narrative
The model no.Of the product (dormia basket) was unknown but a representative product was chosen for processing purposes.(fg-v435p) the used stent during the procedure is not manufactured by olympus; based on the available information, it was determined that olympus devices did not likely cause or contribute to the 3 events; distal migration: 6 patients, stent-induced de novo ductal strictures: 3 patients and fcsems migration: 1 patient.The suspect device has not been returned to olympus for evaluation.The investigation is in process.The literature article is attached for additional information.Once the investigation has been completed, a supplemental report will be submitted with device evaluation results.
 
Manufacturer Narrative
This report is being supplemented to provide additional information based on the legal manufacturer's final investigation.The device history record was unable to be reviewed for this device since the serial and/or lot number was not provided.However, olympus only releases products to market that meet all manufacturing specifications and final product release criteria.Based on the results of the investigation, the relationship between the device and the adverse events cannot be confirmed.There was no complaint reported on the subject device.There is no evidence of an olympus device malfunction.Therefore, the root cause cannot be determined.Olympus will continue to monitor field performance for this device.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EVIS EXERA II DUODENOVIDEOSCOPE
Type of Device
DUODENOVIDEOSCOPE
Manufacturer (Section D)
AIZU OLYMPUS CO., LTD.
3-1-1 niiderakita
aizuwakamatsu-shi, fukushima 965-8 520
JA  965-8520
Manufacturer (Section G)
AIZU OLYMPUS CO., LTD.
3-1-1 niiderakita
aizuwakamatsu-shi, fukushima
Manufacturer Contact
todd brill
800 west park drive
westborough, MA 01581
5082077661
MDR Report Key16508502
MDR Text Key310950216
Report Number9610595-2023-03981
Device Sequence Number1
Product Code FDT
UDI-Device Identifier04953170339967
UDI-Public04953170339967
Combination Product (y/n)N
Reporter Country CodeIN
PMA/PMN Number
K143153
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Other,Foreign,Study,Literature,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 05/03/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberTJF-Q180V
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Initial Date Manufacturer Received 02/06/2023
Initial Date FDA Received03/08/2023
Supplement Dates Manufacturer Received04/11/2023
Supplement Dates FDA Received05/03/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Reuse
Patient Sequence Number1
Patient Outcome(s) Other;
-
-